Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

NCT00458705 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG: bortezomib
DRUG: dexamethasone
DRUG: pegylated liposomal doxorubicin hydrochloride
DRUG: thalidomide

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]